Blastomycosis Market By Formulation (Tablets, Ointment, Powder, Liquid), By Drug Type (Azoles, Polyenes, Others), By Distribution Channel (Hospital and Clinical Pharmacy, Online Pharmacy, Retail Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021-2031
Blastomycosis is a type of fungal infection caused by the fungus Blastomyces dermatitidis, which grows in wood and soil. Spores of Blastomyces enter the body through air, when inhaled, thus it mainly affects the lung and causes pneumonia. Fungi are spread through the bloodstream to other parts of the body. The symptoms of blastomycosis are often similar to the symptoms of other lung infections and can include cough, night sweats, muscle aches or joint pain, weight loss, chest pain, and fatigue.
When blastomycosis infection is spread in the skin, treatments such as azole, allylamines, echinocandins, and polyenes can be given in mild to moderate cases of blastomycosis infection.
Major factors driving the growth of the blastomycosis market include a rise in the development of new medicine for the treatment of blastomycosis infection, an increase in the prevalence rate of chronic diseases such as pneumonia, tuberculosis, a non-infectious pulmonary disease that have led to increases in a number of blastomycosis patients, and high adoption of azoles for the treatment of blastomycosis. Further, growth in the incidence and prevalence rate of infectious diseases and the rise in the population of immunocompromised (prone to infectious diseases) individuals enhance the growth of this market.
For instance, according to the Centers for Disease Control and Prevention, 7,860 tuberculosis (TB) cases were reported in the U.S. in 2021 (a rate of 2.4 per 100,000 persons). In the U.S., up to 13 million people live with latent TB infection. This has led to an increase in the number of blastomycosis patients, which increases the demand for blastomycosis treatment. Hence, such factors drive the growth of blastomycosis treatment.
For instance, according to World Health Organization (WHO), 34.8 million people were living with HIV worldwide in 2021 and 650,000 people died of HIV-related illnesses worldwide in 2021. According to this 1.5 million people acquiring HIV in 2021. Hence, these HIV patients are more vulnerable to blastomycosis, owing to weak immunity to HIV.
However, unfavorable reimbursements as well as complications such as high costs of medicine and drugs for blastomycosis are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for blastomycosis medicine manufacturers worldwide in the future.
Furthermore, the healthcare business is projected to witness growth owing to a rise in immunocompromised patients, a rise in the prevalence of acquired immunodeficiency syndrome (AIDS), that are more vulnerable to blastomycosis, and a boost in the growth of the blastomycosis market. In addition, an increase in the discovery & development of safe and effective medicine for blastomycosis and a rise in awareness regarding the use of azoles for the treatment of blastomycosis drive the growth of the blastomycosis market. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.
Moreover, a rise in R&D investments, an increase in azoles-assisted clinical research studies, a significant rise in the capital income in developed countries, and a surge in key strategies such as acquisition, collaboration, and product launch, adopted by key players strengthen the demand for blastomycosis in the market.
For instance, in June 2021, Celon Laboratories Pvt. Ltd. announced the launch of AMFIGHT, an amphotericin B emulsion, used in the treatment of fungal infection. The emulsion-based formulation is an ideal alternative to Liposomal Amphotericin B to combat the Black Fungus. Though Celon has been manufacturing Liposomal Amphotericin B since 2013, market demands were not met due to the unavailability of a critical ingredient sourced from Germany — lipoids. To bypass the bottleneck caused by this sourcing obstacle and increase the production of this medication, Celon developed an alternative, an emulsion-based formulation. The launch of AMFIGHT will help the company to strengthen its anti-fungal product portfolio. This type of product launch boosts the growth of the blastomycosis market.
The blastomycosis market is segmented on the basis of formulation, drug type, distribution channel, and region. On the basis of formulation, the market is classified into tablets, ointment, powder, and liquid. On the basis of drug type, the market is classified into azoles, polyenes, and others. Depending on the distribution channel, it is fragmented into hospital & clinical pharmacy, online pharmacy, and retail pharmacy. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major players profiled in the report are Abbott Laboratories, Astellas Pharma Inc., Celon Laboratories Pvt. Ltd., Cipla Ltd, GlaxoSmithKline plc, Johnson and Johnson, Merck KGaA, Pfizer Inc., Sanofi S.A., and Sun Pharmaceutical Industries Ltd.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the blastomycosis market analysis from 2021 to 2031 to identify the prevailing blastomycosis market opportunities.
Market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
An in-depth analysis of the blastomycosis market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes an analysis of the regional as well as global blastomycosis market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Type
By Distribution Channel
Hospital and Clinical Pharmacy
Rest of Europe
Rest of Asia-Pacific
Rest of LAMEA
Key Market Players
Merck and Company
johnson and johnson md&d
CELON LABORATORIES LIMITED
Sun Pharmaceuticals Ltd
Astellas Pharma Inc.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook